X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abaloparatide (94) 94
osteoporosis (73) 73
postmenopausal women (58) 58
index medicus (55) 55
teriparatide (45) 45
fractures (34) 34
bone-mineral density (33) 33
romosozumab (30) 30
parathyroid hormone (27) 27
pharmacology & pharmacy (26) 26
endocrinology & metabolism (22) 22
humans (22) 22
vertebral fractures (19) 19
alendronate (17) 17
bone mineral density (17) 17
denosumab (17) 17
parathyroid-hormone (17) 17
female (15) 15
orthopedics (15) 15
postmenopausal osteoporosis (15) 15
bones (14) 14
density (13) 13
endocrinology (13) 13
parathyroid hormone-related protein - therapeutic use (13) 13
rheumatology (12) 12
animals (11) 11
bone (11) 11
bone density (11) 11
bone density - drug effects (11) 11
bone density conservation agents - therapeutic use (11) 11
bone resorption (11) 11
osteoporosis - drug therapy (11) 11
post-menopause (11) 11
pth (11) 11
therapy (11) 11
hip fracture (10) 10
medicine & public health (10) 10
prevention (10) 10
vertebrae (10) 10
zoledronic acid (10) 10
bisphosphonates (9) 9
bone growth (9) 9
drug therapy (9) 9
hormone replacement therapy (9) 9
parathyroid hormone-related protein - pharmacology (9) 9
risk factors (9) 9
teriparatide - therapeutic use (9) 9
women (9) 9
mineral density (8) 8
osteogenesis (8) 8
osteoporosis, postmenopausal - drug therapy (8) 8
parathyroid-hormone 1-34 (8) 8
risk (8) 8
antibodies, monoclonal - therapeutic use (7) 7
care and treatment (7) 7
double-blind (7) 7
osteoporotic fractures - prevention & control (7) 7
parathyroid hormone-related protein (7) 7
trial (7) 7
aged (6) 6
anabolic agents (6) 6
bone density conservation agents - pharmacology (6) 6
fracture (6) 6
fracture risk (6) 6
internal medicine (6) 6
obstetrics & gynecology (6) 6
original (6) 6
parathyroid (6) 6
rats (6) 6
review (6) 6
sclerostin (6) 6
abaloparatide-sc (5) 5
aged, 80 and over (5) 5
amino acids (5) 5
analysis (5) 5
antiresorptive therapy (5) 5
biocompatibility (5) 5
bone turnover (5) 5
drugs (5) 5
epidemiology (5) 5
femur (5) 5
fracture risk reduction (5) 5
frax (5) 5
hormone-related protein (5) 5
medicine, general & internal (5) 5
menopause (5) 5
middle aged (5) 5
odanacatib (5) 5
original article (5) 5
original research (5) 5
ovariectomy (5) 5
parathyroid hormone-related protein - administration & dosage (5) 5
parathyroid hormone[1-34] (5) 5
peptides (5) 5
randomized controlled-trial (5) 5
receptor (5) 5
strontium ranelate (5) 5
vitamin d (5) 5
anabolic agents - pharmacology (4) 4
anabolic agents - therapeutic use (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Roux, C and Briot, K
NATURE REVIEWS RHEUMATOLOGY, ISSN 1759-4790, 02/2018, Volume 14, Issue 2, pp. 67 - 68
A large number of patients with osteoporosis are not receiving appropriate treatment, due in part to concerns regarding drug safety. Great progress has been... 
ABALOPARATIDE | ROMOSOZUMAB | PREVENTION | FRACTURES | RHEUMATOLOGY | POSTMENOPAUSAL WOMEN | ALENDRONATE
Journal Article
Clinical and experimental rheumatology, ISSN 0392-856X, 11/2018, Volume 36, Issue 6, pp. 948 - 958
Osteoporosis is a generalised bone disease characterised by decreased bone mass and deterioration of bone microarchitecture predisposing to fragility... 
romosozumab | glucocorticoid induced osteoporosis | ANTIRESORPTIVE THERAPY | BONE-MINERAL DENSITY | POST HOC ANALYSIS | VERTEBRAL FRACTURE | teriparatide | RHEUMATOLOGY | osteoporosis | TERIPARATIDE RHPTH(1-34) | abaloparatide | ORAL CORTICOSTEROIDS | ABALOPARATIDE-SC | PARATHYROID-HORMONE | POSTMENOPAUSAL WOMEN | RECEPTOR AGONIST
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 12/2019, Volume 34, Issue 12, pp. 2213 - 2219
ABSTRACT In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous... 
ABALOPARATIDE | BONE MINERAL DENSITY | POSTMENOPAUSAL OSTEOPOROSIS | FRACTURE PREVENTION | BASELINE RISK SUBGROUPS | Original
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 08/2017, Volume 32, Issue 8, pp. 1625 - 1631
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 12/2019, Volume 35, Issue 12, pp. 2097 - 2102
Objective: To evaluate, post hoc, the efficacy and safety of abaloparatide by degree of renal impairment. Methods: ACTIVE was a phase 3, 18-month, randomized,... 
Osteoporosis | bone regeneration | abaloparatide | renal insufficiency | bone density conservation agents | postmenopausal
Journal Article
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, ISSN 0002-7863, 09/2019, Volume 141, Issue 37, pp. 14486 - 14490
The type-1 parathyroid hormone receptor (PTHR1), which regulates calcium homeostasis and tissue development, has two native agonists, parathyroid hormone (PTH)... 
POTENT | ABALOPARATIDE | LIGANDS | PTH | ANALOGS | ARRESTIN | AMINO-ACID RESIDUES | SELECTIVITY | CHEMISTRY, MULTIDISCIPLINARY | PEPTIDE | CONFORMATIONS
Journal Article
Clinical Cases in Mineral and Bone Metabolism, ISSN 1724-8914, 05/2016, Volume 13, Issue 2, pp. 106 - 109
Abaloparatide is an investigational analog of human PTHrP (1-34) being developed for the treatment of osteoporosis. The amino-acid sequence of abaloparatide is... 
Osteoporosis | Anabolics | Abaloparatide | PTHrP analogs | anabolics | osteoporosis | abaloparatide | Mini-Review
Journal Article
Current Opinion in Rheumatology, ISSN 1040-8711, 07/2019, Volume 31, Issue 4, pp. 376 - 380
PURPOSE OF REVIEWMany physicians have long considered anabolic osteoporosis medication to be the last resort for patients after multiple fractures have already... 
romosozumab | bone building | DENOSUMAB | PREVENTION | EXTENSION | teriparatide | RHEUMATOLOGY | FRACTURE RISK | ALENDRONATE | ZOLEDRONIC ACID | abaloparatide | anabolic | POSTMENOPAUSAL WOMEN
Journal Article
脊髄外科, ISSN 0914-6024, 2018, Volume 32, Issue 1, pp. 19 - 23
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 09/2019, Volume 859, p. 172550
Postmenopausal osteoporosis, mainly caused by osteoclast-induced bone resorption, has become a global public health burden. Natural compounds are emerging as... 
Bone resorption | RANKL | Osteoclast | Glycyrrhizic acid | Postmenopausal osteoporosis | RATS | RISK | STRONTIUM RANELATE | WOMEN | FRACTURE | ABALOPARATIDE | PARTICLE-INDUCED OSTEOLYSIS | DOWNSTREAM | PHARMACOLOGY & PHARMACY | BONE | KIDNEY
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 02/2019, Volume 509, Issue 4, pp. 960 - 965
Osteoarthritis (OA) is a degenerative joint disease characterized by a progressive loss of articular cartilage. Mesenchymal stem cells transplanted to damaged... 
Abaloparatide | Reactive oxygen species | Chondrogenesis | Osteoarthritis | Mesenchymal stem cells | OXIDATIVE STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CULTURE | CELL-DEATH | HYPERTROPHY | BIOPHYSICS | PARATHYROID-HORMONE | DIFFERENTIATION
Journal Article
Bone Reports, ISSN 2352-1872, 12/2019, Volume 11, p. 100230
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we... 
Postmenopausal | Osteoporosis | Abaloparatide | Alendronate | Bone regeneration | Bone density conservation agents
Journal Article
Menopause, ISSN 1072-3714, 02/2018, Volume 25, Issue 7, pp. 767 - 771
OBJECTIVE:Advanced age is an important risk factor for fracture. The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) trial showed that... 
Osteoporosis | Abaloparatide | Bone mineral density | Postmenopausal women | Fracture risk | Older | HIP FRACTURE | EFFICACY | SAFETY | ELDERLY-WOMEN | RISEDRONATE | OBSTETRICS & GYNECOLOGY | Aged women | Bones | Drug therapy | Health aspects | Density
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.